During the past decade, various adoptive cellular therapies (ACTs) have shown great potential in difficult-to-treat diseases, especially in the treatment of cancer. Different strategies for adoptive cellular immunotherapy have been developed using a variety of cell sources - engineered/ex vivo-expanded lymphocytes are the most promising therapeutic modalities in this field. Most recently, engineered lymphocytes (CAR-T/NK and TCR-T cells) have shown remarkable efficacy in blood cancers compared with conventional treatments. We aim to provide our readers with the latest updates in the field of cellular therapies, with a focus on both blood cancer and solid tumors.
Despite the success of CAR-T cell therapy in blood cancers, we are still facing serious challenges in expanding the indicated conditions and improving the safety and efficacy of this therapy. Notably, there has been extensive investment in the research and development of engineered/ex vivo-expanded lymphocytes from both academia and industry in recent years. A vast majority of interests involve oncology applications of CAR-T, CAR-NK, TCR-T, ?d T cells, and tumor-infiltrating lymphocytes (TILs). On the other hand, manufacturing issues such as extended “vein-to-vein” times and shortage of viral vectors are still bottlenecks that limit the wider use of cellular therapies for patients. Therefore, options that can simplify the manufacturing process and enhance the robustness of CAR T cell production are urgently needed. There are also interests in using allogeneic, off-the-shelf, or stem cell-derived T/NK cells to increase accessibility and decrease the cost of therapies.
With the rapid expansion of cellular therapies and the emerging cutting-edge technologies, this Research Topic intends to provide an updated overview of their expanding applications. We welcome various types of submissions including Original Research, Review, Mini Review, Opinion, Clinical Trial, and Case Reports. Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section.
This Research Topic will cover, but is not limited to, the following themes:
• Up to date perspectives in any one adoptive cellular therapy or the whole field
• Oncology applications of adoptive cellular therapies
• Novel targets and emerging applications of adoptive cellular therapies
• T cell armoring strategies
• Regulation of ACTs, e.g. by microbiota or inflammatory cytokines
• Combination therapies
Dr. Shou is currently a full-time employee at AstraZeneca. The other Editors declare no competing interests.
Note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section.
During the past decade, various adoptive cellular therapies (ACTs) have shown great potential in difficult-to-treat diseases, especially in the treatment of cancer. Different strategies for adoptive cellular immunotherapy have been developed using a variety of cell sources - engineered/ex vivo-expanded lymphocytes are the most promising therapeutic modalities in this field. Most recently, engineered lymphocytes (CAR-T/NK and TCR-T cells) have shown remarkable efficacy in blood cancers compared with conventional treatments. We aim to provide our readers with the latest updates in the field of cellular therapies, with a focus on both blood cancer and solid tumors.
Despite the success of CAR-T cell therapy in blood cancers, we are still facing serious challenges in expanding the indicated conditions and improving the safety and efficacy of this therapy. Notably, there has been extensive investment in the research and development of engineered/ex vivo-expanded lymphocytes from both academia and industry in recent years. A vast majority of interests involve oncology applications of CAR-T, CAR-NK, TCR-T, ?d T cells, and tumor-infiltrating lymphocytes (TILs). On the other hand, manufacturing issues such as extended “vein-to-vein” times and shortage of viral vectors are still bottlenecks that limit the wider use of cellular therapies for patients. Therefore, options that can simplify the manufacturing process and enhance the robustness of CAR T cell production are urgently needed. There are also interests in using allogeneic, off-the-shelf, or stem cell-derived T/NK cells to increase accessibility and decrease the cost of therapies.
With the rapid expansion of cellular therapies and the emerging cutting-edge technologies, this Research Topic intends to provide an updated overview of their expanding applications. We welcome various types of submissions including Original Research, Review, Mini Review, Opinion, Clinical Trial, and Case Reports. Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section.
This Research Topic will cover, but is not limited to, the following themes:
• Up to date perspectives in any one adoptive cellular therapy or the whole field
• Oncology applications of adoptive cellular therapies
• Novel targets and emerging applications of adoptive cellular therapies
• T cell armoring strategies
• Regulation of ACTs, e.g. by microbiota or inflammatory cytokines
• Combination therapies
Dr. Shou is currently a full-time employee at AstraZeneca. The other Editors declare no competing interests.
Note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section.
